Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $6
Ascendiant Capital analyst Edward Woo maintains IGC Pharma (AMEX:IGC) with a Buy and raises the price target from $5.5 to $6.
Read original at benzingaStocks · News reference
IGC Pharma Says Phase 2 CALMA Trial Of IGC-AD1 In Alzheimer's Agitation Has Randomized 160 Participants To Date, With Topline Results Expected In Q4 2026
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 11, 2026, 12:36 PM
- Checked
- Aug 11, 2026, 12:36 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
IGC Pharma Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $265.000K Beat $258.000K Estimate
IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 50 percent decrease over losses of $(0.02) per share from the same
Read original at benzinga'THC And CBD From Marijuana Reduces Agitation In 9 Out Of 10 People With Alzheimer’s Or Other Dementia, Study Shows' - Marijuana Moment
https://www.marijuanamoment.net/thc-and-cbd-from-marijuana-reduces-agitation-in-9-out-of-10-people-with-alzheimers-or-other-dementia-study-shows/
Read original at benzinga